ENANTA PHARMACEUTICALS, INC Shareholders' Equity
ENANTA PHARMACEUTICALS, INC (ENTA) had Shareholders' Equity of $101.07 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2026-06-30: Stockholders' Equity Attributable to Parent $101.07M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $116.59M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $126.59M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $64.72M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $101.07M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $116.59M 10-Q · filed 2026-08-12 |
| 2025-12-31 | $126.59M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $64.72M 10-Q · filed 2026-08-12 |
| 2025-06-30 | $79.28M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $93.54M 10-Q · filed 2026-08-12 |
| 2024-12-31 | $111.82M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $128.81M 10-Q · filed 2026-08-12 |
| 2024-06-30 | $148.91M 10-Q · filed 2025-08-13 |
| 2024-03-31 | $166.11M 10-Q · filed 2025-08-13 |
| 2023-12-31 | $191.88M 10-Q · filed 2025-08-13 |
| 2023-09-30 | $216.74M 10-K · filed 2025-11-19 |
| 2023-06-30 | $237.82M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $269.38M 10-Q · filed 2024-08-07 |
| 2022-12-31 | $300.84M 10-Q · filed 2024-08-07 |
| 2022-09-30 | $321.33M 10-K · filed 2025-11-19 |
| 2022-06-30 | $338.02M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $358.58M 10-Q · filed 2023-08-08 |
| 2021-12-31 | $384.38M 10-Q · filed 2023-08-08 |
| 2021-09-30 | $399.43M 10-K · filed 2024-11-27 |
| 2021-06-30 | $417.85M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $436.03M 10-Q · filed 2022-08-08 |
| 2020-12-31 | $452.00M 10-Q · filed 2022-08-08 |
| 2020-09-30 | $455.58M 10-K · filed 2023-11-22 |
| 2020-06-30 | $480.56M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $485.99M 10-Q · filed 2021-08-09 |
| 2019-12-31 | $482.29M 10-Q · filed 2021-08-09 |
| 2019-09-30 | $462.49M 10-K · filed 2022-11-23 |
| 2019-06-30 | $448.10M 10-Q · filed 2020-08-10 |
| 2019-03-31 | $436.21M 10-Q · filed 2020-08-10 |
| 2018-12-31 | $426.83M 10-Q · filed 2020-08-10 |
| 2018-09-30 | $393.68M 10-K · filed 2021-11-24 |
| 2018-06-30 | $360.90M 10-Q · filed 2019-08-09 |
| 2018-03-31 | $333.40M 10-Q · filed 2019-08-09 |
| 2017-12-31 | $317.58M 10-Q · filed 2019-08-09 |
| 2017-09-30 | $301.68M 10-K · filed 2020-11-25 |
| 2017-06-30 | $260.87M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $266.01M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $268.17M 10-Q · filed 2017-02-09 |
| 2016-09-30 | $269.94M 10-K · filed 2019-11-27 |
| 2016-06-30 | $269.01M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $266.42M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $264.28M 10-Q · filed 2016-02-09 |
| 2015-09-30 | $236.16M 10-K · filed 2018-11-29 |
| 2015-06-30 | $228.28M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $224.22M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $193.71M 10-Q · filed 2015-02-06 |
| 2014-09-30 | $148.65M 10-K · filed 2017-12-11 |
| 2014-06-30 | $152.95M 10-Q · filed 2014-08-12 |
| 2014-03-31 | $101.72M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $105.58M 10-Q · filed 2014-02-13 |
| 2013-09-30 | $110.47M 10-K · filed 2016-12-09 |
| 2013-06-30 | $114.41M 10-Q · filed 2013-08-12 |
| 2013-03-31 | $118.38M 10-Q · filed 2013-05-15 |
| 2012-09-30 | -$115.35M 10-K · filed 2015-12-11 |
| 2011-09-30 | -$131.96M 10-K · filed 2014-12-11 |
| 2010-09-30 | -$150.07M 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |